• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在高危患者中实现了目标收缩压(120-140mmHg)下的舒张压和脉压,并取得了心血管结局:ONTARGET 和 TRANSCEND 试验的结果。

Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.

机构信息

Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, 66421 Homburg/Saar, Germany.

Statistical Consultant, 55216 Ingelheim, Germany.

出版信息

Eur Heart J. 2018 Sep 1;39(33):3105-3114. doi: 10.1093/eurheartj/ehy287.

DOI:10.1093/eurheartj/ehy287
PMID:29873709
Abstract

AIMS

Current guidelines of hypertensive management recommend upper limits for systolic (SBP) and diastolic blood pressure (DBP). J-curve associations of BP with risk exist for some outcomes suggesting that lower limits of DBP goals may also apply. We examined the association between mean attained DBP and cardiovascular (CV) outcomes in patients who achieved an on-treatment SBP in the range of 120 to <140 mmHg in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in ACE iNtolerant participants with cardiovascular Disease (TRANSCEND) trials on patients with high CV risk. This SBP range was associated with the lowest CV risk.

METHODS

We analysed the outcome data from patients age 55 years or older with CV disease from the ONTARGET and TRANSCEND trials that randomized high-risk patients to ramipril, telmisartan, and the combination. In patients with controlled SBP (on-treatment 120 to <140 mmHg), the composite outcome of CV death, myocardial infarction, stroke and hospital admission for heart failure, the components thereof, and all-cause mortality were analysed according to mean on-treatment DBP as categorical (<70, 70 to <80, 80 to <90, and ≥90 mmHg) and continuous variable as well as the change of DBP according to baseline DBP. Pulse pressure (PP) was related to outcomes as a continuous variable.

RESULTS

In 16 099 of 31 546 patients, mean achieved SBP was 120 to <140 mmHg. The nominally lowest risk for all outcomes was observed at an achieved DBP of 70 to <80 mmHg. A higher achieved DBP was associated with a higher risk for the outcomes of stroke and of hospitalization for heart failure (≥80 mmHg) and myocardial infarction (≥90 mmHg). A lower achieved DBP (<70 mmHg) was associated with a higher risk for the primary outcome [hazard ratio (HR) 1.29, 95% confidence interval (95% CI) 1.15-1.45; P < 0.0001], myocardial infarction HR 1.54 (95% CI 1.26-1.88, P < 0.0001) and hospitalization for heart failure HR 1.81 (95% CI 1.47-2.24, P < 0.0001) and all-cause death (HR 1.19, 95% CI 1.04-1.35; P < 0.0001) while there was no signal for stroke and CV death compared to DBP 70 to <80 mmHg. A decrease of DBP was associated with lower risk when baseline DBP was >80 mmHg. The associations to outcomes were similar when patients were divided to SBP 120 to <130 mmHg or 130 to <140 mmHg for DBP or PP.

CONCLUSION

Compared to a DBP of 70 to <80 mmHg, lower and higher DBP was associated with a higher risk in patients achieving a SBP of 120 to <140 mmHg. Associations of DBP and PP to risk were similar notably at controlled SBP. These data suggest at optimal achieved SBP, risk is still defined by low or high DBP. These findings support guidelines which take DBP at optimal SBP control into consideration.

摘要

目的

当前的高血压管理指南建议收缩压(SBP)和舒张压(DBP)的上限。对于某些结果,BP 与风险之间存在 J 曲线关联,这表明 DBP 目标的下限也可能适用。我们研究了在 Ongoing Telmisartan Alone 和 in Combination with Ramipril Global Endpoint Trial(ONTARGET)和 Telmisartan Randomized AssessmeNt Study in ACE iNtolerant participants with cardiovascular Disease(TRANSCEND)试验中,在治疗期间 SBP 达到 120 至 <140mmHg 的范围内,达到的平均 DBP 与心血管(CV)结果之间的关联在患有高 CV 风险的患者中。该 SBP 范围与最低 CV 风险相关。

方法

我们分析了来自 ONTARGET 和 TRANSCEND 试验的年龄在 55 岁或以上且患有 CV 疾病的患者的结局数据,这些患者随机分配接受雷米普利、替米沙坦和联合治疗。在 SBP 得到控制(治疗期间 120 至 <140mmHg)的患者中,根据治疗期间 DBP 的分类(<70、70 至 <80、80 至 <90 和≥90mmHg)和连续变量以及根据基线 DBP 测量的 DBP 变化,分析 CV 死亡、心肌梗死、中风和心力衰竭住院的复合结局、其组成部分和全因死亡率。脉压(PP)作为连续变量与结局相关。

结果

在 31546 名患者中的 16099 名患者中,平均达到的 SBP 为 120 至 <140mmHg。所有结局中,风险最低的是达到的 DBP 为 70 至 <80mmHg。较高的达到的 DBP 与中风和心力衰竭住院(≥80mmHg)和心肌梗死(≥90mmHg)的结局风险较高相关。较低的达到的 DBP(<70mmHg)与主要结局(风险比 [HR] 1.29,95%置信区间 [95%CI] 1.15-1.45;P<0.0001)、心肌梗死 HR 1.54(95%CI 1.26-1.88,P<0.0001)和心力衰竭住院 HR 1.81(95%CI 1.47-2.24,P<0.0001)和全因死亡(HR 1.19,95%CI 1.04-1.35;P<0.0001)的风险较高相关,而与 DBP 为 70 至 <80mmHg 相比,没有中风和 CV 死亡的信号。当基线 DBP>80mmHg 时,DBP 下降与较低的风险相关。当患者根据 DBP 分为 SBP 120 至 <130mmHg 或 130 至 <140mmHg 或 PP 时,与结局的关联相似。

结论

与 DBP 为 70 至 <80mmHg 相比,在达到 SBP 为 120 至 <140mmHg 的患者中,较低和较高的 DBP 与更高的风险相关。DBP 和 PP 与风险的关联在 SBP 得到良好控制时也相似。这些数据表明,在达到最佳的 SBP 时,风险仍然由低或高 DBP 定义。这些发现支持将最佳 SBP 控制下的 DBP 纳入考虑的指南。

相似文献

1
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.在高危患者中实现了目标收缩压(120-140mmHg)下的舒张压和脉压,并取得了心血管结局:ONTARGET 和 TRANSCEND 试验的结果。
Eur Heart J. 2018 Sep 1;39(33):3105-3114. doi: 10.1093/eurheartj/ehy287.
2
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.在高危患者中实现血压和心血管结局:ONTARGET 和 TRANSCEND 试验结果。
Lancet. 2017 Jun 3;389(10085):2226-2237. doi: 10.1016/S0140-6736(17)30754-7. Epub 2017 Apr 5.
3
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.心血管结局和高心血管风险患者的糖尿病与非糖尿病患者的血压控制情况。
Eur Heart J. 2019 Jul 1;40(25):2032-2043. doi: 10.1093/eurheartj/ehz149.
4
Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.VALUE 试验中高血压患者不同治疗时血压的心血管结局。
Eur Heart J. 2016 Mar 21;37(12):955-64. doi: 10.1093/eurheartj/ehv633. Epub 2015 Nov 20.
5
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).糖尿病患者的低血压安全性和疗效:ONTARGET(替米沙坦单独和与雷米普利联合的全球终点试验)的亚组分析。
J Am Coll Cardiol. 2012 Jan 3;59(1):74-83. doi: 10.1016/j.jacc.2011.09.040.
6
Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients.ONTARGET 和 TRANSCEND 患者治疗中平均血压和随访间血压变异性的相对和综合预后重要性。
Hypertension. 2017 Nov;70(5):938-948. doi: 10.1161/HYPERTENSIONAHA.117.09714. Epub 2017 Oct 3.
7
Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk.在心血管疾病高危的糖尿病患者和非糖尿病患者中,肾脏结局和血压模式。
J Hypertens. 2021 Apr 1;39(4):766-774. doi: 10.1097/HJH.0000000000002697.
8
A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.一项使用动态血压监测对轻度至中度高血压患者进行的替米沙坦和雷米普利的多中心、为期14周的研究。
Am J Hypertens. 2006 Jan;19(1):104-12. doi: 10.1016/j.amjhyper.2005.10.001.
9
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.在接受替米沙坦、雷米普利或两者联合治疗的高危患者中,勃起功能障碍可预测心血管事件:ONTARGET/TRANSCEND 试验(替米沙坦单独和与雷米普利联合用于不耐受 ACE 抑制剂的心血管疾病患者的全球终点试验/替米沙坦随机评估研究)。
Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15.
10
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.高血压合并冠状动脉疾病患者的脉压与心血管事件风险:一项国际维拉帕米缓释片 - 群多普利研究(INVEST)分析
Eur Heart J. 2009 Jun;30(11):1395-401. doi: 10.1093/eurheartj/ehp109. Epub 2009 Apr 7.

引用本文的文献

1
The effect of ambulatory blood pressure load on mitral regurgitation in continuous ambulatory peritoneal dialysis patients.动态血压负荷对持续性非卧床腹膜透析患者二尖瓣反流的影响。
Open Med (Wars). 2025 Apr 1;20(1):20251155. doi: 10.1515/med-2025-1155. eCollection 2025.
2
Sex Differences in Achieved Diastolic Blood Pressure and Cardiovascular Outcomes in Elderly Patients With Hypertension.老年高血压患者舒张期血压达标情况及心血管结局的性别差异
JACC Adv. 2025 Apr;4(4):101675. doi: 10.1016/j.jacadv.2025.101675. Epub 2025 Mar 20.
3
Effects of key physiological parameters on cardiovascular disease and osteoporosis risk in perimenopausal and postmenopausal women.
关键生理参数对围绝经期和绝经后女性心血管疾病及骨质疏松症风险的影响。
Sci Rep. 2025 Jan 22;15(1):2814. doi: 10.1038/s41598-025-86613-8.
4
Association of Changes in Relevant Indicators With Cardiovascular Disease and Osteoporosis in Perimenopausal and Postmenopausal Women.围绝经期和绝经后女性相关指标变化与心血管疾病和骨质疏松症的关联
Food Sci Nutr. 2024 Nov 6;12(12):10296-10305. doi: 10.1002/fsn3.4512. eCollection 2024 Dec.
5
In-hospital pulse pressure variability: A novel marker of cardiovascular risk among patients with coronary artery disease undergoing percutaneous coronary intervention?住院期间脉压变异性:经皮冠状动脉介入治疗的冠心病患者心血管风险的新标志物?
Int J Cardiol Heart Vasc. 2024 Jun 15;53:101445. doi: 10.1016/j.ijcha.2024.101445. eCollection 2024 Aug.
6
Development a nomogram prognostic model for survival in heart failure patients based on the HF-ACTION data.基于 HF-ACTION 数据开发心力衰竭患者生存预测列线图模型。
BMC Med Inform Decis Mak. 2024 Jul 19;24(1):197. doi: 10.1186/s12911-024-02593-1.
7
Association of triglyceride glucose-body mass index with Alzheimer's disease pathology, cognition and brain structure in non-demented people.甘油三酯-葡萄糖-体重指数与非痴呆人群阿尔茨海默病病理、认知和大脑结构的关系。
Sci Rep. 2024 Jul 12;14(1):16097. doi: 10.1038/s41598-024-67052-3.
8
Elevated pulse pressure preceded incident chronic kidney disease in the general older population in Sweden.在瑞典的一般老年人群中,脉压升高先于慢性肾脏病事件的发生。
Sci Rep. 2024 Jul 4;14(1):15414. doi: 10.1038/s41598-024-66458-3.
9
Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes.诊室血压测量与动态血压监测:在伴或不伴糖尿病患者中的死亡率相关性。
Eur Heart J. 2024 Aug 16;45(31):2851-2861. doi: 10.1093/eurheartj/ehae337.
10
Risk factors of in-hospital mortality and discriminating capacity of NIVO score in exacerbations of COPD requiring noninvasive ventilation.慢性阻塞性肺疾病急性加重期需要无创通气时院内死亡的危险因素及NIVO评分的鉴别能力
Chron Respir Dis. 2024 Jan-Dec;21:14799731241249474. doi: 10.1177/14799731241249474.